Why SELLAS Life Sciences (SLS) Stock Rose 156% on Nov 17: A Phase 3 Filing, Then a $150M Offering
SELLAS Life Sciences jumped 156% on a Phase 3 8-K, but an offering prospectus filing landed the same day. BILL Holdings rose on a takeover report alone, and AECOM on earnings and a dividend raise.

A record of verified facts, not stock advice. Screen: three U.S. stocks that closed up 10% or more in the regular session on Nov 17 (local time). The reason was confirmed by a filing or news report for all three (two by filing, one by report only). Figures as of 07:00 KST, Nov 18, 2026.

Seoul — SELLAS Life Sciences (SLS) closed up 156.36% at $19.15 on Nov 17 in New York. An 8-K, the current report companies file with the U.S. Securities and Exchange Commission, confirms the cause: Phase 3 trial results. But an offering prospectus was filed the same day. BILL Holdings (BILL) rose 12.58% on a takeover report with no company filing, and AECOM (ACM) rose 11.08% on an earnings-and-dividend 8-K. The S&P 500 fell 1.03%, the Nasdaq Composite 0.74% and the Russell 2000 small-cap index 1.50%. Yahoo's markets blog said losses deepened ahead of Nvidia's earnings and that Salesforce fell more than 9%.
At a glance
| Stock | Why it rose | Nature | Evidence | Heat | What to check next |
|---|---|---|---|---|---|
| SELLAS Life Sciences (SLS) +156.36% | Positive Phase 3 leukemia vaccine results | Substantive, one-off (offering attached) | Filing confirmed | 3/4 strong overheating | Final offering price and size; next-day dollar volume |
| BILL Holdings (BILL) +12.58% | Report that TPG is nearing a take-private deal | Expectation | Report only | 2/4 overheated | Official confirmation from the company or TPG |
| AECOM (ACM) +11.08% | Quarterly results, record backlog, 10% dividend raise | Substantive, continuing | Filing confirmed | 1/4 caution | Revenue trend; dividend payment date |
SELLAS Life Sciences rose 156% on Phase 3 results, and an offering filing came the same day

The driver is a Phase 3 readout for an acute myeloid leukemia (AML) vaccine candidate. According to an 8-K (Items 7.01, 8.01, 9.01) filed with the SEC, the company announced on Nov 17 positive topline results from the pivotal randomized Phase 3 REGAL trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine. The trial used GPS as maintenance monotherapy in patients in second or later complete remission who could not undergo a stem cell transplant. What the filing confirms is that the company called the results positive. A Stock Titan headline cites Phase 3 survival of 24 versus 14.7 months, though the headline alone does not say which arm is which.
The catch is a 424B5 (prospectus supplement) filed the same day. marketscreener and StreetInsider reported a planned $150 million common stock offering, and Investing.com's headline said the stock fell on the news. The size and price in the 424B5 itself could not be confirmed; the $150 million figure comes from the reports. Against a market value of about $3.9 billion, the offering is roughly 3.8%. The $19.15 close is about 2.6 times the prior day's $7.47 and 61.2% above the Oct 14 close of $11.88. But the stock had fallen nearly 37% from $11.88 to $7.47 in between, so the move recovered that drop and went further. Dollar volume was about $2.29 billion. Views on the data differ: Asianet Newsable reported that Martin Shkreli called the results 'sketch.'
Overheating check: 3 of 4 signals. The price is 92.0% above its 20-day average, volume is 15.6 times the 20-day average and the 5-day gain is 128.8%; RSI is 75.4. It sits at the top of its 52-week range (0.0% off the high) and 115.7% above its 200-day line. It passes 1 of 5 fundamentals checks: it is not profitable and free cash flow is not positive. The 8-K reads as favorable, the 424B5 as a caution. On Nov 12 the company filed an earnings 8-K (Item 2.02) and a 10-Q, unrelated to this jump.
Two things show whether the gain holds. One is the final offering price and size, and how far they sit from $19.15 in follow-up filings. The other is whether volume stays near 15 times normal the next day, and what detailed Phase 3 numbers the company releases.
BILL Holdings rose 19% in two days on a takeover report (the company has said nothing)

The reason is a report that TPG is nearing a deal to take BILL Holdings private. Yahoo relayed a Financial Times report citing people familiar with the matter, and Benzinga said the stock hit a 52-week high on it. But the company filed nothing about it. The only filings on Nov 17 were two Form 144s, notices of planned insider stock sales, whose contents could not be confirmed.
The close of $64.88 is up 19.1% over two days (from the Nov 13 close) and 20.7% over five. On a market value of about $5.57 billion, dollar volume was about $657 million. The stock also rose 5.78% on Nov 16, and no headline explains that move. This is an expectation built on a report; if the deal fails or the price disappoints, the gain could unwind.
Overheating check: 2 of 4 signals. RSI is 91.9 and volume is 6.7 times the 20-day average. The stock is at its 52-week high (0.0% off) and 50.8% above its 200-day line. It passes 4 of 6 fundamentals checks (profitable, positive free cash flow, acceptable debt, revenue growth of 12.5%), and its P/E is 124.8.
Watch for BILL Holdings or TPG confirming or denying the deal in an 8-K or similar filing. If it becomes official, the offer price versus $64.88 is the next yardstick, along with who filed the two Form 144s and how much they plan to sell.
AECOM rose 11% on earnings and a dividend raise (confirmed by filing)

The cause is the earnings and dividend in an 8-K (Items 2.02, 8.01, 9.01) dated Nov 16. The company reported results for fiscal 2026, which ended Sept 30, and raised its quarterly dividend 10%, from $0.31 to $0.34 a share. According to Yahoo, fourth-quarter adjusted EPS rose 20% to $1.63, backlog hit a record $28 billion and the fiscal 2027 earnings outlook beat estimates. The close was $80.53.
There is a counterpoint. Another Yahoo article said earnings beat but sales fell short, and the computed revenue growth is -14.2%. The record backlog and dividend raise are lasting items, but if revenue does not grow, earnings expectations alone may not hold the price. Baird raised its price target from $65 to $86 the same day (Benzinga).
Overheating check: 1 of 4 signals. RSI of 90.4 is the one that applies; volume is 3.2 times the 20-day average, the price is 21.1% above its 20-day line and the 5-day gain is 14.0%. It sits at 33% of its 52-week range, 36.7% below the high, and 8.1% above its 200-day line. It passes 3 of 6 fundamentals checks (profitable, positive free cash flow, ROE above 10%), and its P/E is 28.4. The filing reads as favorable.
To judge whether this lasts, watch whether the $28 billion backlog turns into revenue and whether sales stop shrinking next quarter. The dividend is payable on Jan 22, 2027 to holders of record on Jan 6.
FAQ
Why did they rise? SELLAS on Phase 3 results, BILL Holdings on a TPG takeover report, AECOM on earnings and a dividend raise.
Which filings support it? SELLAS: an 8-K (7.01, 8.01, 9.01) and a 424B5 on Nov 17. AECOM: an 8-K (2.02, 8.01, 9.01) on Nov 16. BILL Holdings has no filing explaining the move.
What is the next scheduled date? AECOM's dividend record date is Jan 6, 2027 and payment date Jan 22. No dates have been set for SELLAS's final offering terms or for any BILL Holdings confirmation.
How the stocks we covered last time fared
Closes through Nov 17. 'Verdict then' is the evidence category in our earlier article.
| Stock | Verdict then | Close then | Close Nov 17 | Change |
|---|---|---|---|---|
| Modine Manufacturing (MOD) | Report | 135.66 | 129.73 | -4.4% |
| Liftoff Mobile (LFTO) | Earnings | 24.44 | 22.68 | -7.2% |
| Stantec (STN) | Earnings | 85.69 | 82.78 | -3.4% |
| Mobility Global (MBGL) | Filing | 23.13 | 23.89 | +3.3% |
| Chagee (CHA) | Report | 13.51 | 13.69 | +1.3% |
| Belite Bio (BLTE) | Report | 169.96 | 157.72 | -7.2% |
| CoreWeave, Inc. (CRWV) | Earnings | 60.77 | 49.89 | -17.9% |
| Azenta, Inc. (AZTA) | Earnings | 48.90 | 45.81 | -6.3% |
All four stocks we covered on earnings fell afterward, with CoreWeave down the most at 17.9%. The three that rose on reports alone split: -4.4%, +1.3% and -7.2%. Mobility Global, confirmed by filing, gained 3.3%. With the S&P 500 down 1.03% on the day, it is hard to separate each stock's catalyst from the market's effect.
FAQ
Why did SELLAS Life Sciences stock go up?
Positive Phase 3 leukemia vaccine results. Evidence: Filing confirmed. What to check next: 3/4 strong overheating.
Why did BILL Holdings stock go up?
Report that TPG is nearing a take-private deal. Evidence: Report only. What to check next: 2/4 overheated.
Why did AECOM stock go up?
Quarterly results, record backlog, 10% dividend raise. Evidence: Filing confirmed. What to check next: 1/4 caution.